Spedra Phoenix Labs Unlimited Company · Authorised · authorised 21 Jun 2013 · ATC G04BE10
Therapeutic indication (EMA)
Treatment of erectile dysfunction in adult men. In order for Spedra to be effective, sexual stimulation is required.
Active substance
Avanafil
- SFDA 10
- US FDA 2
- EMA 1
- US price lines 1
- NHS prices 6
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| SPEDRA 100 mg Tablet | 100 mg | Tablet · Oral use | 4 Blister | SAR 59.00 | NCE · Prescription | SANOFI WINTHROP INDUSTRIE | Valid |
| SPEDRA 200 mg Tablet | 200 mg | Tablet · Oral use | 4 Blister | SAR 59.00 | NCE · Prescription | SANOFI WINTHROP INDUSTRIE | Valid |
| SPEDRA 50 mg Tablet | 50 mg | Tablet · Oral use | 4 Blister | SAR 54.50 | NCE · Prescription | SANOFI WINTHROP INDUSTRIE | Valid |
| Vantra | 100 mg | Tablet · Oral use | 4 Blister | SAR 55.05 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Vantra | 200 mg | Tablet · Oral use | 4 Blister | SAR 55.05 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Vantra | 50 mg | Tablet · Oral use | 4 Blister | SAR 44.25 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| Vantra | 50 mg | Tablet · Oral use | 12 Blister | SAR 132.75 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| Vantra | 50 mg | Tablet · Oral use | 30 Blister | SAR 331.85 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| Vantra | 100 mg | Tablet · Oral use | 12 Blister | SAR 143.85 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| Vantra | 200 mg | Tablet · Oral use | 12 Blister | SAR 143.85 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BENIGN PROSTATIC HYPERTROPHY
US FDA United States — FDA approvals (Drugs@FDA)
EMA European Union — centrally authorised medicines
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | AVANAFIL 200 MG TABLET | $49.99744 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Avanafil 100mg tablets | £14.08 | 4 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Avanafil 100mg tablets | £26.26 | 8 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Avanafil 200mg tablets | £21.90 | 4 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Avanafil 200mg tablets | £39.40 | 8 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Avanafil 50mg tablets | £10.94 | 4 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Avanafil 50mg tablets | £19.70 | 8 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 18 Oct 2022 STENDRA — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.